Established in 2014, SignalPath designed its CTMS platform to enhance the ease, quality and efficacy with which clinical research is carried out at trial sites.
The CTMS also reduces fragmentation by using a modern software architecture and a Cloud-based platform to help a trial site manage its clinical trials portfolio.
SignalPath’s technology infrastructure facilitates new methods for partners to significantly recover the expenses, complexities and time related to clinical trials.
The deal with Verily will enable SignalPath to offer clinical research sites with access to an emerging portfolio of resources, tools and trial opportunities.
SignalPath co-founder and CEO Brad Hirsch said: “Combining these capabilities with Verily’s clinical studies platforms business accelerates our ability to scale these solutions and make them available to a larger group of sites, as well as provide entirely new opportunities to our network.”
Verily expects the acquisition to boost its current clinical trial system and evidence generation platform called Baseline.
Baseline allows improved and quicker trial execution, enhanced data aggregation and analysis, as well as flexible options for decentralised and hybrid trials.
The platform also enables the capture of real-world data, including data from new sensors and biomarkers.
The Baseline community currently includes more than 500,000 people with an interest to be part of clinical research. These individuals are automatically linked with research opportunities based on their interests and profiles.
Verily Clinical Studies Platforms president Amy Abernethy said: “Joining forces helps to accelerate and scale our shared vision, increase efficiency and lower costs in clinical trials, empower clinical research sites with world-class technology, and ultimately bring medicines to patients faster.”
At the closing of the acquisition, SignalPath employees will become part of Verily’s clinical research business and remain in Raleigh, North Carolina, US, expanding the latter’s geographic presence.